Answers are grounded in this paper and cite their sources.
Pleural mesothelioma is a rare disease with few therapeutic options, especially in the first line refractory setting. Targeted agents did not demonstrate a significant clinical benefit in mesothelioma treatment, nevertheless a small group of patients might harbor potentially actionable somatic mutations, as in homologous repair recombination genes. In this paper we report two cases of patients with heavily pretreated pleural mesothelioma that had a relevant clinical benefit with rucaparib treatment based on somatic BRCA 1 and BRCA 2 mutations detected through next generation sequencing.
No takes yet. Share an insight, caveat, or question.
Cerbone et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: